Consensus Guidelines for the Design and Implementation of Clinical Trials in ALS. World Federation of Neurology Committee on Research

Overview

Journal J Neurol Sci

Publisher Elsevier

Specialty Neurology

Date 1999 Dec 14

PMID 10540001

Citations 39

Authors

R G Miller

T L Munsat

M Swash

B R Brooks

Affiliations

Soon will be listed here.

Abstract

Background: In 1994 consensus guidelines were developed for conducting clinical trials in ALS. With growing experience in clinical trials, it has become clear that a number of further guidelines were needed.

Methods: Under the auspices of the World Federation of Neurology Committee on Research, a multinational group of neurologists, statisticians, patient advocates, representatives from the pharmaceutical industry as well as regulatory agencies developed consensus about a number of revisions to the existing guidelines during a 2 day conference in April 1998.

Results: Expanded areas of focus include greater protection of patient rights, more detailed guidelines for outcome measures statistical analyses, disclosure of study results and improved interaction between investigators and the corporate sector.

Comment: Substantial progress has been made in standardizing and improving the quality of clinical trials in ALS through these consensus guidelines.

Citing Articles

Limbic Network and Papez Circuit Involvement in ALS: Imaging and Clinical Profiles in GGGGCC Hexanucleotide Carriers in and -Negative Patients.

Christidi F, Kleinerova J, Tan E, Delaney S, Tacheva A, Hengeveld J Biology (Basel). 2024; 13(7).

PMID: 39056697 PMC: 11273537. DOI: 10.3390/biology13070504.

Efficacy of non-pharmacological interventions for individuals with amyotrophic lateral sclerosis: systematic review and network meta-analysis of randomized control trials.

Li Z, Kang H Sci Rep. 2024; 14(1):11365.

PMID: 38762656 PMC: 11102473. DOI: 10.1038/s41598-024-62213-w.

A Diagnostic Gene-Expression Signature in Fibroblasts of Amyotrophic Lateral Sclerosis.

Morello G, La Cognata V, Guarnaccia M, La Bella V, Conforti F, Cavallaro S Cells. 2023; 12(14).

PMID: 37508548 PMC: 10378077. DOI: 10.3390/cells12141884.

Considerations on the concept, definition, and diagnosis of amyotrophic lateral sclerosis.

Xu R, Yuan M Neural Regen Res. 2021; 16(9):1723-1729.

PMID: 33510061 PMC: 8328770. DOI: 10.4103/1673-5374.306065.

Diffusion kurtosis and quantitative susceptibility mapping MRI are sensitive to structural abnormalities in amyotrophic lateral sclerosis.

Welton T, Maller J, Lebel R, Tan E, Rowe D, Grieve S Neuroimage Clin. 2019; 24:101953.

PMID: 31357149 PMC: 6664242. DOI: 10.1016/j.nicl.2019.101953.